The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes.

Shami, Dalia; Sousou, John M; Batarseh, Einas; Alazrai, Laith

Shami, Dalia; Sousou, John M; Batarseh, Einas; Alazrai, Laith.

Afiliación

Shami D; General Practice, AlMahabba Hospital, Madaba, JOR.
Sousou JM; Internal Medicine, Lake Erie College of Osteopathic Medicine, Jacksonville, USA.
Batarseh E; Internal Medicine, University of Buffalo, Buffalo, USA.
Alazrai L; Internal Medicine, Jordanian Royal Medical Services, Amman, JOR.

Cureus ; 15(1): e33484, 2023 Jan.

Article en En | MEDLINE | ID: mdl-36751181

Palabras clave

cardio-renal cascade; cardiovascular disease risk; glp-1 receptor agonists; hyperglycemia management; sodium-glucose cotransporter-2 (sglt-2) inhibitors; type-2 diabetes mellitus

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Cureus Año: 2023 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google